

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Muscle Relaxants

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
Member/Subscriber Number:	Supervising Physician:
Date of Birth:	Fax: Phone:
Group Number:	Office Contact:
Address:	NPI: State Lic ID:
City, State ZIP:	Address:
Primary Phone:	City, State ZIP:
	Specialty/facility name (if applicable):

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Which medication is being requested? <input type="checkbox"/> Carisoprodol <input type="checkbox"/> Chlorzoxazone <input type="checkbox"/> Methocarbamol <input type="checkbox"/> Orphenadrine Citrate ER <input type="checkbox"/> Other
Q2. What indication will the requested medication be used for? <input type="checkbox"/> Acute, painful musculoskeletal conditions <input type="checkbox"/> Other (Please explain)
Q3. Please provide ICD code(s) for indication being treated.
Q4. Is member greater than or equal to 65 years? <input type="checkbox"/> Yes <input type="checkbox"/> No

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Muscle Relaxants

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:

Q5. The requested medication has been identified by CMS as a high-risk medication when used in patients age 65 and older. The prescriber should consider the risks and benefits of treatment prior to initiating therapy. Ongoing monitoring for adverse effects and reevaluation of risk versus benefit should be considered for continuation of therapy as the risks increase with patient age.

Q6. Additional comments:

Prescriber Signature

Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document